The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
This is a non-interventional, observational study of archived human tissue samples; no surgical procedures will be required and no treatment will be provided as part of this study. Approximately 150 archived tissue samples obtained from patients with iCCA or mixed HCC-CCA will be analyzed for somatic alteration status and will include cholangiocarcinoma-specific FGFR2 fusion isoforms.
Study Type
OBSERVATIONAL
Enrollment
131
Unnamed facility
Atlanta, Georgia, United States
Unnamed facility
Seattle, Washington, United States
Unnamed facility
Rozzano, MI, Italy
Unnamed facility
Benevento, Italy
Unnamed facility
Estimate the frequency of FGFR2 fusions in archived iCCA or mixed HCC-CCA tumor tissue samples
Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.
Time frame: Archived tumor samples will be collected through study completion, up to 18 months
Determine the frequency of potential actionable mutations or genetic alterations in iCCA or mixed HCC-CCA
Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.
Time frame: Archived tumor samples will be collected through study completion, up to 18 months
Formulate genetic screening recommendations for newly diagnosed patients with iCCA or mixed HCC-CCA
Archived tumor samples will be collected and analyzed using a Next Generation Sequencing panel.
Time frame: Archived tumor samples will be collected through study completion, up to 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Milan, Italy
Unnamed facility
Pisa, Italy